Wednesday, June 10, 2026

pharma Β· Dermatitis atopic Β· Cancer

Sanofi-Aventis U.S

Sanofi-Aventis U.S clinical programs β€” 51 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
Status
Public
HQ
Bridgewater, USA
Employees
177
Programs
117
Drugs
148
Patents
0
Intelligence Β· Clinical Programs

Sanofi-Aventis U.S projects

51 ClinicalTrials.gov programs sponsored by Sanofi-Aventis U.S.

Sanofi-Aventis U.S has 51 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Chronic inflammatory demyelinating polyradiculoneuropathy

    phase 2 small molecule active

    1 trial
  2. riliprubart, riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Transplant Rejection

    phase 2 small molecule active

    1 trial
  3. sarilumab

    Sanofi-aventis Healthcare Pty Ltd

    Systemic Juvenile Idiopathic Arthritis (sJIA)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Sanofi-Aventis U.S have?

51 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.